Posted by Michael Wonder on 16 Mar 2022
Submission of oral edarvarone formulation, MT-1186 new drug application in Japan for ALS
14 March 2022 - Mitsubishi Tanabe Pharma announced that the company has submitted to the MHLW in Japan an application for the manufacturing and marketing approval of an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis on 14 March 2022.
MT-1186 is an oral suspension formulation that contains the same active ingredient as edaravone for intravenous infusion (Japanese product name: Radicut Injection 30 mg and Radicut Bag for I.V. Infusion 30 mg) for ALS treatment.
